Nanotechnology for Psoriasis Therapy

Abstract

To summarize the use of nanotechnology-based drug delivery systems for psoriasis therapies, focusing on recent studies of treatment efficacy in humans and murine models. Both topical and oral psoriasis medications, in addition to alternative psoriasis therapies and siRNAs targeting genes involved in the pathogenesis of psoriasis, have been incorporated into nanocarriers. Numerous studies demonstrate that nanocarriers can enhance the efficacy and reduce side effects of their included drugs through increased skin retention, sustained release, and decreased systemic absorption. However, the number of studies in humans is limited and while the short-term use of nanocarriers appears safe, long-term outcomes are unknown. Additionally, few studies compare different types of nanocarriers, making it difficult to recommend which types of nanocarriers are the best. While recent research has demonstrated the benefit of nanotechnology-based drug delivery systems for psoriasis, more research, especially in humans, is needed to optimize drug-loaded nanocarriers for clinical use.